Adrenalectomy for incidental and symptomatic phaeochromocytoma: retrospective multicentre study based on the Eurocrine® database.
Adrenal Gland Neoplasms
/ complications
Adrenal Insufficiency
/ etiology
Adrenalectomy
/ adverse effects
Adrenergic alpha-Antagonists
/ therapeutic use
Aged
Conversion to Open Surgery
Female
Humans
Hypertension
/ etiology
Length of Stay
Male
Middle Aged
Pheochromocytoma
/ complications
Postoperative Complications
Retrospective Studies
Tumor Burden
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
23 10 2021
23 10 2021
Historique:
received:
11
01
2021
accepted:
05
05
2021
pubmed:
17
7
2021
medline:
15
12
2021
entrez:
16
7
2021
Statut:
ppublish
Résumé
Phaeochromocytoma is sometimes not diagnosed before surgery and may present as an adrenal incidentaloma. The aim of this study was to investigate differences in clinical presentation and perioperative outcome in patients with subclinical and symptomatic phaeochromocytoma, and in patients operated with and without preoperative α-blockade. This was a retrospective observational study of patients with a histopathological diagnosis of phaeochromocytoma registered in Eurocrine®, the European registry for endocrine tumours, between 1 January 2015 and 31 March 2020. Patient characteristics, clinical presentation, tumour detection, and perioperative variables were analysed. Some 551 patients were included. Of these, 486 patients (88.2 per cent) had a preoperative diagnosis of phaeochromocytoma. Tumours were detected as incidentalomas in 239 patients (43.4 per cent) and 265 (48.1 per cent) had a preoperative diagnosis of hypertension. Preoperative α-blockade was more frequently used in patients with a known phaeochromocytoma (350, 90.9 per cent) than in patients with other indications for adrenalectomy (16, 31 per cent). Complications did not differ between patients who had surgery because of catecholamine excess compared with those who had other indications for surgery (19 (3.9 per cent) versus 2 (3 per cent); P = 0.785), nor did the conversion rate from minimally invasive to open surgery differ between the groups. There were no obvious differences in complications, according to the Clavien-Dindo classification, based on preoperative α-blockade or not. Subclinical phaeochromocytoma detected incidentally is common. A significant proportion of patients with phaeochromocytoma did not have α-blockade before surgery, without an apparent effect on complications. Phaeochromocytoma is an unusual adrenal tumour with hormonal overproduction of catecholamines leading to a severe condition, including extreme hypertension in some situations. It is treated with surgery. Medical treatment before surgery is used to minimize surgical complications related to high blood pressure. A large proportion of phaeochromocytomas are detected incidentally, without symptoms, on radiological examination for other reasons. The aim of this study was to investigate differences in patient characteristics and surgical results in patients operated with or without symptoms of phaeochromocytoma. Patients registered in the large, European database, Eurocrine®, between 2015 and 2020 were included in the study. The study showed that phaeochromocytoma without symptoms is common. Medical treatment before surgery does not seem to affect complications.
Sections du résumé
BACKGROUND
Phaeochromocytoma is sometimes not diagnosed before surgery and may present as an adrenal incidentaloma. The aim of this study was to investigate differences in clinical presentation and perioperative outcome in patients with subclinical and symptomatic phaeochromocytoma, and in patients operated with and without preoperative α-blockade.
METHODS
This was a retrospective observational study of patients with a histopathological diagnosis of phaeochromocytoma registered in Eurocrine®, the European registry for endocrine tumours, between 1 January 2015 and 31 March 2020. Patient characteristics, clinical presentation, tumour detection, and perioperative variables were analysed.
RESULTS
Some 551 patients were included. Of these, 486 patients (88.2 per cent) had a preoperative diagnosis of phaeochromocytoma. Tumours were detected as incidentalomas in 239 patients (43.4 per cent) and 265 (48.1 per cent) had a preoperative diagnosis of hypertension. Preoperative α-blockade was more frequently used in patients with a known phaeochromocytoma (350, 90.9 per cent) than in patients with other indications for adrenalectomy (16, 31 per cent). Complications did not differ between patients who had surgery because of catecholamine excess compared with those who had other indications for surgery (19 (3.9 per cent) versus 2 (3 per cent); P = 0.785), nor did the conversion rate from minimally invasive to open surgery differ between the groups. There were no obvious differences in complications, according to the Clavien-Dindo classification, based on preoperative α-blockade or not.
CONCLUSION
Subclinical phaeochromocytoma detected incidentally is common. A significant proportion of patients with phaeochromocytoma did not have α-blockade before surgery, without an apparent effect on complications.
Phaeochromocytoma is an unusual adrenal tumour with hormonal overproduction of catecholamines leading to a severe condition, including extreme hypertension in some situations. It is treated with surgery. Medical treatment before surgery is used to minimize surgical complications related to high blood pressure. A large proportion of phaeochromocytomas are detected incidentally, without symptoms, on radiological examination for other reasons. The aim of this study was to investigate differences in patient characteristics and surgical results in patients operated with or without symptoms of phaeochromocytoma. Patients registered in the large, European database, Eurocrine®, between 2015 and 2020 were included in the study. The study showed that phaeochromocytoma without symptoms is common. Medical treatment before surgery does not seem to affect complications.
Autres résumés
Type: plain-language-summary
(eng)
Phaeochromocytoma is an unusual adrenal tumour with hormonal overproduction of catecholamines leading to a severe condition, including extreme hypertension in some situations. It is treated with surgery. Medical treatment before surgery is used to minimize surgical complications related to high blood pressure. A large proportion of phaeochromocytomas are detected incidentally, without symptoms, on radiological examination for other reasons. The aim of this study was to investigate differences in patient characteristics and surgical results in patients operated with or without symptoms of phaeochromocytoma. Patients registered in the large, European database, Eurocrine®, between 2015 and 2020 were included in the study. The study showed that phaeochromocytoma without symptoms is common. Medical treatment before surgery does not seem to affect complications.
Identifiants
pubmed: 34270711
pii: 6321579
doi: 10.1093/bjs/znab199
pmc: PMC10364866
doi:
Substances chimiques
Adrenergic alpha-Antagonists
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1199-1206Investigateurs
T Musholt
(T)
F Palazzo
(F)
M Almquist
(M)
M Barczynski
(M)
T Clerici
(T)
M Vriens
(M)
M Raffaelli
(M)
Ö Makay
(Ö)
N Munos Pérez
(N)
M H Hansen
(MH)
L Brunaud
(L)
S Van Slycke
(S)
P Riss
(P)
M Iacobone
(M)
E Nordenström
(E)
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
Surgery. 2014 Dec;156(6):1410-7; discussion1417-8
pubmed: 25456922
Front Endocrinol (Lausanne). 2018 Nov 27;9:515
pubmed: 30538672
Br J Anaesth. 2017 Feb;118(2):182-189
pubmed: 28100521
Endocrine. 2010 Feb;37(1):40-6
pubmed: 19882253
Endocr Rev. 2003 Aug;24(4):539-53
pubmed: 12920154
Best Pract Res Clin Endocrinol Metab. 2012 Aug;26(4):507-15
pubmed: 22863392
Eur J Endocrinol. 2009 Aug;161(2):355-61
pubmed: 19497985
J Clin Endocrinol Metab. 2020 Sep 1;105(9):
pubmed: 32609829
Crit Rev Oncol Hematol. 2016 Apr;100:190-208
pubmed: 26839173
JAMA Surg. 2018 Nov 1;153(11):1036-1041
pubmed: 30090934
Langenbecks Arch Surg. 2017 Mar;402(2):315-322
pubmed: 27896436
J Clin Endocrinol Metab. 2013 Nov;98(11):4346-54
pubmed: 24001749
J Clin Endocrinol Metab. 2012 Jun;97(6):2077-83
pubmed: 22492870
Lancet Diabetes Endocrinol. 2020 Nov;8(11):894-902
pubmed: 33065059
Nat Rev Cancer. 2014 Feb;14(2):108-19
pubmed: 24442145
BMC Urol. 2020 Jun 9;20(1):66
pubmed: 32517679
Surgery. 2020 Jan;167(1):250-256
pubmed: 31543324
Br J Surg. 2020 Jan;107(2):e102-e108
pubmed: 31903584
Ann Clin Biochem. 2018 Jan;55(1):34-48
pubmed: 29027806
J Clin Endocrinol Metab. 2000 Feb;85(2):637-44
pubmed: 10690869
Eur J Endocrinol. 2016 Aug;175(2):G1-G34
pubmed: 27390021
Am J Hypertens. 1996 Aug;9(8):760-9
pubmed: 8862222
Eur J Endocrinol. 2019 Oct;181(4):409-420
pubmed: 31370000
Clin Chem. 2005 Apr;51(4):735-44
pubmed: 15718487
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Nat Rev Endocrinol. 2015 Feb;11(2):101-11
pubmed: 25385035
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135